Biogen reanalyzes studies, presses ahead on Alzheimer’s drug

Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer’s disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia.

The announcement was a surprise because the drug company earlier this year stopped two studies of the drug when partial results suggested it was not likely to be successful. The company now says a new analysis of more results suggest that the drug helped reduce a decline of thinking skills at the highest dose.

The drug, called aducanumab, aims to help the body clear harmful plaques from the brain. Cambridge, Massachusetts-based Biogen is developing it with a Japanese company, Eisai Co. Ltd.

More than 5 million people in the United States and millions more worldwide have Alzheimer’s. Current drugs only temporarily ease symptoms and do not slow the loss of memory and thinking skills. Dozens of efforts to develop a drug to slow or reverse the course of the disease have failed.

The two studies tested aducanumab, given as monthly infusions, in more than 3,000 patients with mild cognitive impairment or early dementia due to Alzheimer’s. The company said Tuesday that in one study, those given a high dose showed 23% less decline on one measure of thinking skills and smaller declines on other measures.

However, no details were given on how much that decline meant in absolute terms. For example, the company didn’t say how much difference it made in practical matters, like whether patients were able to dress or feed themselves or live independently longer, just that these skills overall declined less for those on the high dose of the drug.

“It’s a tricky question” whether the results are truly meaningful for patients until more details are known, said Dr. Ronald Petersen, a Mayo Clinic dementia specialist who has consulted for Biogen on the studies.

But filing for federal Food and Drug Administration approval “gives some hopes for patients and families that there may be disease-modifying therapies out there,” he said.

The company said more details would be given at a conference in December, including on safety. The company said the most common side effects were inflammation in the brain, most of which did not cause symptoms or lasting problems, and headaches. The brain inflammation has been seen in other studies of Alzheimer’s medicines that target the brain plaques.

“We’re really encouraged by the information that they’ve provided today,” the largest benefit so far for any experimental medicine, said Rebecca Edelmayer, a scientist at the Alzheimer’s Association, which had no role in the studies.

Biogen said it would offer aducanumab now to patients enrolled in these and earlier studies of it.

Biogen shares were up more than 26% to $281.87 Tuesday, but some on Wall Street remained skeptical.

Mizuho Securities USA analyst Salim Syed said he wants to know more about the FDA’s involvement in Biogen’s decision. He also said in a research note that it’s still just a hypothesis that removing beta amyloid plaques can benefit Alzheimer’s patients.

The company’s announcement “does not guarantee approval and questions remain,” he said.

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

A sign on a shop window indicates the store is closed in Ottawa, Monday March 23, 2020. The Canadian Federation of Independent Business is raising its estimate for the number of businesses that are considering the possibility of closing permanently. THE CANADIAN PRESS/Adrian Wyld
Alberta entrepreneur launches project to help small business owners

Bruce Tannas is trying to bring together small businesses as the COVID-19… Continue reading

Alberta Premier Jason Kenney updates media in Edmonton on measures taken to help with COVID-19 on Friday, March 20, 2020. Political analysts say Kenney must rethink his traditional “fight back” approach and start building bridges to reconcile environmental concerns with oil and gas development. THE CANADIAN PRESS/Jason Franson
Political scientists say Kenney must rethink pugilistic approach on oil, environment

Keystone XL pipeline expansion would have taken more oil from Alberta through the United States to refineries and ports

An incomplete secondary wall stands alongside the previous version near where the border separating Tijuana, Mexico, and San Diego meets the Pacific Ocean Tuesday, Jan. 19, 2021, in Tijuana, Mexico. In the days before Joe Biden became president, construction crews worked quickly to finish Donald Trump’s wall at an iconic cross-border park overlooking the Pacific Ocean that then-first lady Pat Nixon inaugurated in 1971 as symbol of international friendship. (AP Photo/Gregory Bull)
Biden halts border wall building after Trump’s final surge

Pause order leaves billions of dollars of work unfinished but still under contract

Former Alberta Premier Rachel Notley shakes hands with Joel Ward, former Red Deer College President and CEO, as Notley announces that the college is on the path to grant degrees. Red Deer-South MLA Jason Stephan says university status is not a necessary condition for offering degrees. (File photo by Advocate staff)
Future of Red Deer University increasingly uncertain

MLA’s college update says RDC more like SAIT and NAIT than a university

There are two confirmed COVID-19 cases at Red Deer College. Photo by Mamta Lulla/Advocate staff
Central Albertans were promised a university

Central Albertans were promised a university

Jacqueline Donahue of Hazleton, right, buys la Mega Millions lottery ticket at the Anthracite Newsstand on Public Square, Monday, Jan. 18, 2021, in Wilkes-Barre, Pa. (Mark Moran/The Citizens’ Voice via AP)
Nearly $1B Mega Millions prize due to long odds, slow sales

Only the third time a lottery jackpot has grown so large

David Shoemaker, chief executive officer of the Canadian Olympic Committee, speaks during the Olympic Partnership kick off event at the Sobey’s office in Mississauga, Ont. on Monday, October 7, 2019. Shoemaker says the IOC remains committed to staging the Summer Games in Tokyo this summer. THE CANADIAN PRESS/ Tijana Martin
Canadian Olympic boss says IOC plans to go ahead with Tokyo Games this summer

IOC calls cancellation decision “categorically untrue”

FILE - In this Jan. 24, 2011 file photo, Dustin Diamond attends the SYFY premiere of “Mega Python vs. Gatoroid” at The Ziegfeld Theater in New York. Diamond is undergoing chemotherapy treatments after being diagnosed with cancer, according to his representative. Diamond, best known for playing Screech on the hit ’90s sitcom, was hospitalized earlier this month in Florida. Last week, his team disclosed he did have cancer. (AP Photo/Peter Kramer, File)
Dustin Diamond undergoing chemotherapy treatments for cancer

Diamond hospitalized earlier this month in Florida

Winnipeg Jets' Mark Scheifele, left, and Kyle Connor, right, congratulate Blake Wheeler on his goal during second period NHL action against the Ottawa Senators on Thursday, January 21, 2021 in Ottawa. THE CANADIAN PRESS/Adrian Wyld
Four different Jets score as Winnipeg beats the Ottawa Senators 4-1

Four different Jets score as Winnipeg beats the Ottawa Senators 4-1

Most Read